Marshall Wace LLP Increases Stake in Express Scripts Holding Co (ESRX)

Marshall Wace LLP increased its holdings in Express Scripts Holding Co (NASDAQ:ESRX) by 23.1% in the third quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 435,742 shares of the company’s stock after buying an additional 81,792 shares during the quarter. Marshall Wace LLP owned about 0.08% of Express Scripts worth $41,400,000 at the end of the most recent reporting period.

A number of other hedge funds have also modified their holdings of ESRX. Acadian Asset Management LLC bought a new position in Express Scripts in the 2nd quarter worth approximately $314,000. Migdal Insurance & Financial Holdings Ltd. grew its holdings in Express Scripts by 3,048.1% in the 2nd quarter. Migdal Insurance & Financial Holdings Ltd. now owns 1,637 shares of the company’s stock worth $126,000 after buying an additional 1,585 shares in the last quarter. Connor Clark & Lunn Investment Management Ltd. grew its holdings in Express Scripts by 44.7% in the 2nd quarter. Connor Clark & Lunn Investment Management Ltd. now owns 32,125 shares of the company’s stock worth $2,480,000 after buying an additional 9,925 shares in the last quarter. Adviser Investments LLC boosted its stake in Express Scripts by 321.9% during the 2nd quarter. Adviser Investments LLC now owns 1,481 shares of the company’s stock valued at $114,000 after purchasing an additional 1,130 shares in the last quarter. Finally, Alps Advisors Inc. boosted its stake in Express Scripts by 10.5% during the 2nd quarter. Alps Advisors Inc. now owns 13,019 shares of the company’s stock valued at $1,005,000 after purchasing an additional 1,238 shares in the last quarter. 85.02% of the stock is owned by institutional investors and hedge funds.

A number of equities analysts have issued reports on ESRX shares. BidaskClub raised Express Scripts from a “hold” rating to a “buy” rating in a research note on Tuesday, September 18th. ValuEngine raised Express Scripts from a “hold” rating to a “buy” rating in a research note on Monday, September 17th. Credit Suisse Group lowered Express Scripts from an “outperform” rating to a “neutral” rating and increased their price target for the company from $90.00 to $96.50 in a research note on Tuesday, September 18th. Mizuho set a $101.00 price target on Express Scripts and gave the company a “hold” rating in a research note on Monday, November 5th. Finally, Royal Bank of Canada increased their price target on Express Scripts to $94.00 and gave the company an “outperform” rating in a research note on Monday, August 27th. One research analyst has rated the stock with a sell rating, fourteen have assigned a hold rating, four have assigned a buy rating and one has assigned a strong buy rating to the stock. The company has an average rating of “Hold” and an average target price of $92.14.

Shares of ESRX traded down $0.66 during trading hours on Friday, hitting $97.32. 40,694 shares of the company were exchanged, compared to its average volume of 4,009,498. The firm has a market cap of $55.75 billion, a PE ratio of 13.72, a P/E/G ratio of 1.25 and a beta of 0.88. The company has a quick ratio of 0.65, a current ratio of 0.77 and a debt-to-equity ratio of 0.63. Express Scripts Holding Co has a one year low of $66.93 and a one year high of $101.73.

Express Scripts (NASDAQ:ESRX) last released its quarterly earnings data on Wednesday, October 31st. The company reported $2.43 earnings per share for the quarter, topping the consensus estimate of $2.42 by $0.01. The business had revenue of $25.56 billion during the quarter, compared to analyst estimates of $25.11 billion. Express Scripts had a return on equity of 25.43% and a net margin of 4.83%. The company’s revenue was up 3.6% compared to the same quarter last year. During the same period last year, the company posted $2.51 EPS. On average, equities research analysts anticipate that Express Scripts Holding Co will post 9.08 EPS for the current fiscal year.

In other news, Director Mahon Thomas P. Mac sold 5,234 shares of the firm’s stock in a transaction on Wednesday, November 7th. The stock was sold at an average price of $99.50, for a total transaction of $520,783.00. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. Company insiders own 0.79% of the company’s stock.

ILLEGAL ACTIVITY NOTICE: “Marshall Wace LLP Increases Stake in Express Scripts Holding Co (ESRX)” was originally published by Chaffey Breeze and is owned by of Chaffey Breeze. If you are reading this story on another publication, it was illegally stolen and republished in violation of US & international trademark and copyright law. The legal version of this story can be read at https://www.chaffeybreeze.com/2018/12/07/marshall-wace-llp-increases-stake-in-express-scripts-holding-co-esrx.html.

Express Scripts Company Profile

Express Scripts Holding Company operates as a pharmacy benefit management (PBM) company in the United States and Canada. The company's PBM segment offers clinical solutions; and specialized pharmacy care, home delivery and specialty pharmacy, retail network pharmacy administration, benefit design consultation, drug utilization review, drug formulary management, public exchange, administration of group purchasing organization, and digital consumer health and drug information services.

Featured Story: Cost of equity and a company’s balance sheet

Institutional Ownership by Quarter for Express Scripts (NASDAQ:ESRX)

Receive News & Ratings for Express Scripts Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Express Scripts and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply